Genentech publishes REGENCY trial data in the New England Journal of Medicine
Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...
FDA approves Susvimo for diabetic macular edema
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...
Endocrinology Advisor5d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Pacific Daily News5d
Documents: Chinese national who fled Saipan over drug debt forced to sell drugs on Guam
A Chinese national escaping a drug debt on Saipan told an FBI agent he fled to Guam by boat but when he arrived here, he was captured by the drug dealer and forced to sell methamphetamine to repay ...
Daily6d
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
MedPage Today6d
Four Medical Schools Probed by HHS; Trump's Autism Claim; Why Is the AMA Quiet?
The HHS Office for Civil Rights said it will start compliance reviews for four medical schools after antisemitic incidents ...
PharmiWeb6d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Business Wire6d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The American Journal of Managed Care6d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
ophthalmologytimes6d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...